755039-55-5

Basic information

• Product Name: (R)-2-CHLORO-8-CYCLOPENTYL-7-ETHYL-5-METHYL-7,8-DIHYDROPTERIDIN-6(5H)-ONE
• Synonyms: (R)-2-CHLORO-8-CYCLOPENTYL-7-ETHYL-5-METHYL-7,8-DIHYDROPTERIDIN-6(5H)-ONE;6(5H)-Pteridinone, 2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro-5-Methyl-, (7R)-;2-Chloro-8-cyclopentyl-7-ethyl-5-Methyl-7,8-dihydro-5H-pteridin-6-one;(7R)-2-Ch;6(5H)-pte;6(5H)-Pteridinone, 2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro-5-Methyl-, (7R)- (7R)-2-Ch;(7R)-2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro-5-Methyl-6(5H)-pteridinone;(7R)-2-chloro-8-cyclopentyl-7-ethyl-5-methyl-5,6,7,8-tetrahydropteridin-6-one
• CAS NO: 755039-55-5
• Molecular Formula: C₁₄H₁₉ClN₄O
• Molecular Weight: 294.77986
• EINECS: 1308068-626-2
• Mol File: 755039-55-5.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 537.5°C at 760 mmHg
• Flash Point: 278.9°C
• Appearance: /
• Density: 1.263g/cm³
• Vapor Pressure: 1.27E-11mmHg at 25°C
• Refractive Index: 1.577
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.45±0.40(Predicted)
• CAS DataBase Reference: (R)-2-CHLORO-8-CYCLOPENTYL-7-ETHYL-5-METHYL-7,8-DIHYDROPTERIDIN-6(5H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-CHLORO-8-CYCLOPENTYL-7-ETHYL-5-METHYL-7,8-DIHYDROPTERIDIN-6(5H)-ONE(755039-55-5)
• EPA Substance Registry System: (R)-2-CHLORO-8-CYCLOPENTYL-7-ETHYL-5-METHYL-7,8-DIHYDROPTERIDIN-6(5H)-ONE(755039-55-5)

Safety Data

• Hazardous Substances Data: 755039-55-5(Hazardous Substances Data)

Usage

General Description

(R)-2-CHLORO-8-CYCLOPENTYL-7-ETHYL-5-METHYL-7,8-DIHYDROPTERIDIN-6(5H)-ONE is a chemical compound that belongs to the class of dihydropteridines. It is a derivative of pteridine and has a cyclopentyl group, an ethyl group, and a methyl group attached to the central ring structure. The compound also contains a chlorine atom at position 2. Dihydropteridines are important precursors in the biosynthesis of tetrahydrobiopterin, a coenzyme that is involved in the synthesis of neurotransmitters and the metabolism of certain amino acids. This particular compound may have potential applications in pharmacology, biochemistry, and medicinal chemistry, and further research may reveal its specific biological activities and interactions.

InChI:InChI=1/C14H19ClN4O/c1-3-10-13(20)18(2)11-8-16-14(15)17-12(11)19(10)9-6-4-5-7-9/h8-10H,3-7H2,1-2H3/t10-/m1/s1

Upstream product

• 755039-54-4 (R)-2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydropteridin-6(5H)-one 
• 616-38-6 carbonic acid dimethyl ester 
• 80-48-8 methyl p-toluene sulfonate 
• 120-92-3 cyclopentanone 
• 74-88-4 methyl iodide 
• 512-56-1 trimethyl phosphite 
• 755039-52-2 (R)-methyl 2-(cyclopentylamino)butanoate 
• 755039-53-3 (R)-methyl 2-((2-chloro-5-nitropyrimidin-4-yl)(cyclopentyl)-amino)butanoate 

Downstream Products

• 1313518-82-9 (R)-8-cyclopentyl-7-ethyl-5-methyl-2-(5-phenylpyridazin-4-yl)-7,8-dihydropteridin-6(5H)-one 
• 1313518-83-0 (R)-8-cyclopentyl-7-ethyl-5-methyl-2-(phenylethynyl)-7,8-dihydropteridin-6(5H)-one 
• 1313516-81-2 (R)-8-cyclopentyl-7-ethyl-5-methyl-2-(2-oxo-2-phenylethyl)-7,8-dihydropteridin-6(5H)-one 
• 1313518-74-9 (R)-8-cyclopentyl-7-ethyl-5-methyl-2-(4-phenylpyrimidin-5-yl)-7,8-dihydropteridin-6(5H)-one 
• 1313518-75-0 (R,Z)-8-cyclopentyl-2-(1-(dimethylamino)-3-oxo-3-phenylprop-1-en-2-yl)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one 
• 1313518-76-1 (R)-8-cyclopentyl-7-ethyl-5-methyl-2-(5-phenylisoxazol-4-yl)-7,8-dihydropteridin-6(5H)-one 
• 1313518-77-2 (R)-8-cyclopentyl-7-ethyl-5-methyl-2-(5-phenyl-1H-pyrazol-4-yl)-7,8-dihydropteridin-6(5H)-one 
• 1313518-78-3 (R)-8-cyclopentyl-7-ethyl-5-methyl-2-(5-phenyl-1H-1,2,4-triazol-1-yl)-7,8-dihydropteridin-6(5H)-one 
• 1313518-80-7 (R)-8-cyclopentyl-7-ethyl-5-methyl-2-(3-phenylpyrazin-2-yl)-7,8-dihydropteridin-6(5H)-one 
• 1313518-81-8 (7R)-2-(1-bromo-2-oxo-2-phenylethyl)-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one 
• 1313519-05-9 (R)-8-cyclopentyl-7-ethyl-5-methyl-2-(2-phenylacetyl)-7,8-dihydropteridin-6(5H)-one 
• 1313519-02-6 (R)-8-cyclopentyl-7-ethyl-5-methyl-2-(4-phenyl-1H-pyrazol-3-yl)-7,8-dihydropteridin-6(5H)-one 
• 1344728-02-4 (R)-N-(2-aminoethyl)-4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzamide 
• 755038-02-9 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide 

Relevant articles and documents

Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a sulfonyl moiety as potent dual inhibitors of PLK1 and BRD4

The simultaneous inhibition of PLK1 and BRD4 by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Herein, two series of novel pteridinone derivatives possessing a sulfonyl moiety were designed, synthesized and evaluated for their biological activity. Most compounds exhibited moderate to excellent cytotoxic activity against HCT116, PC3 and BT474 cell lines. Among them, the most promising compound B2 showed high antiproliferative effects on the three cell lines with IC50 values of 0.30 μM, 1.82 μM and 1.69 μM, respectively. In the enzymatic assay, B2 was identified as a potent PLK1 and BRD4 dual inhibitor (PLK1 IC50 = 6.3 nM, BRD4 IC50 = 179 nM). Further explorations in bioactivity were conducted to clarify the anticancer mechanism of compound B2. The results showed that compound B2 obviously inhibited the proliferation of HCT116 cell lines, induced a great decrease in the mitochondrial membrane potential leading to apoptosis of HCT116 cells and arrested the G2 phase of HCT116 cells.

Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer

Targeting poly(ADP-ribose) polymerase1/2 (PARP1/2) is a promising strategy for the treatment of pancreatic cancer with breast cancer susceptibility gene (BRCA) mutation. Inducing the deficiency of homologous recombination (HR) repair is an effective way t

Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors

The simultaneous inhibition of polo-like kinase 1 (PLK1) and BRD4 bromodomain by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Compound 23 has been found to be a potent dual kinase-bromodomain inhibitor (BRD4-BD1 IC50 = 28 nM, PLK1 IC50 = 40 nM). Compound 6 was found to be the most selective PLK1 inhibitor over BRD4 in our series (BRD4-BD1 IC50 = 2579 nM, PLK1 IC50 = 9.9 nM). Molecular docking studies with 23 and BRD4-BD1/PLK1 as well as with 6 corroborate the biochemical assay results.